4/A: ProMIS Neurosciences: Warrant Exercise Price Correction

An amended SEC filing corrects the exercise price for Title 19 Promis's warrant transactions with ProMIS Neurosciences Inc. to $0.83518 per share.

Summary

• Title 19 Promis, a significant shareholder, filed an amendment to its Form 4, correcting the exercise price of Tranche A, B, and C common share purchase warrants.
• On July 25, 2025, Title 19 Promis exercised 119,800 warrants for each of Tranche A, B, and C, totaling 359,400 common shares.
• The corrected exercise price for all tranches was $0.83518 per share, adjusted from original exercise prices of $2.02 (Tranche A & B) and $2.50 (Tranche C) following an offer and acceptance by the Issuer.
• Following these transactions, Title 19 Promis's ownership in ProMIS Neurosciences Inc. has dropped below 10% based on 51,806,497 common shares outstanding as of August 13, 2025.
• Remaining Tranche A warrants expire within 18 months of issue date or 60 days of 6-month PMN310 data announcement.
• Remaining Tranche B warrants expire within 30 months of issue date or 60 days of 12-month PMN310 data announcement.
• Remaining Tranche C warrants expire on July 31, 2029.

Sentiment

Score: 6

Explanation: The filing is primarily an administrative correction of a minor numerical error. The underlying transaction (warrant exercise at a reduced price) could be viewed as slightly positive for the company if it needed the capital, but also implies a concession or potential dilution. The drop in ownership below 10% for the reporting person is a factual update, not inherently positive or negative for the company's operations.

Positives

• The exercise of warrants by Title 19 Promis at a negotiated lower price of $0.83518 per share, significantly below the original exercise prices of $2.02 and $2.50, indicates a successful negotiation for the warrant holder.
• The company received capital from the warrant exercise, though the amount is not explicitly stated as a positive for the company in the filing itself.

Negatives

• The need for an amendment to correct a numerical error ($0.83158 instead of $0.83518) suggests a minor administrative oversight in the initial filing.
• The significant reduction in exercise price from original terms ($2.02/$2.50 to $0.83518) implies a dilution for existing shareholders if the market price was higher than the reduced exercise price, or a concession made by the company to encourage warrant exercise.

Risks

• The expiration of remaining Tranche A and B warrants is tied to the public announcement of PMN310 clinical trial data (6-month and 12-month data), introducing a dependency on trial outcomes and disclosure timelines.

Future Outlook

The expiration of remaining Tranche A and B warrants is contingent on the public announcement of 6-month and 12-month data from cohorts treated with single ascending doses of PMN310, indicating future milestones related to clinical trial results.

Management Comments

• The Reporting Person's ownership has dropped below 10% as of the date of filing this amended Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was originally filed, the Reporting Person held more than 10% at such time the Form 4 was originally filed.

Industry Context

This filing is specific to an insider transaction and a minor correction, offering limited direct insight into broader industry trends. However, the mention of PMN310 clinical trial data ties it to the biotechnology/pharmaceutical industry's reliance on R&D milestones.

Stakeholder Impact

• Shareholders: Potential minor dilution from the warrant exercise at a reduced price, though the transaction was already reported. The correction itself has no direct impact.
• Warrant Holders (Title 19 Promis): Successfully exercised warrants at a significantly reduced price, benefiting from the negotiation.

Next Steps

• Public announcement via press release or Form 8-K filing of 6-month data from cohorts treated with single ascending doses of PMN310 (relevant for Tranche A warrant expiration).
• Public announcement via press release or Form 8-K filing of 12-month data from cohorts treated with single ascending doses of PMN310 (relevant for Tranche B warrant expiration).

Key Dates

Recommendation

This filing is an administrative amendment correcting a minor numerical error in a previously disclosed insider transaction. It does not contain new material information regarding the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The underlying warrant exercise, while involving a significant shareholder and a negotiated price, is a past event. Investors should hold and await more substantive operational or financial updates.

Keywords

ProMIS Neurosciences, PMN, SEC Form 4/A, beneficial ownership, warrant exercise, equity, common shares, insider trading, Title 19 Promis, PMN310, clinical trial data